Imagine putting tiny magnets into your blood that attract a unique layer of proteins, like a personalized fingerprint. By shining a laser on these particles, we can see if that fingerprint matches the signature of early-stage cancer. It is a way to spot a deadly disease long before it shows up on a traditional scan.
Pancreatic cancer has a survival rate below 10% because it is usually detected too late. There are currently no reliable biomarkers for early-stage screening of the general population.
An FL analysis prototype and a method to identify disease fingerprints using nanoparticle protein coronas in mouse models.
If you are a medical device manufacturer dealing with the lack of reliable biomarkers for early cancer screening — this project developed a laser-based fluorescence lifetime analysis tool that identifies disease progression from its first occurrence. This allows for the creation of a high-sensitivity screening test for the general population.
If you are a nanoparticle developer dealing with the need for new clinical applications for protein corona research — this project developed a method to correlate specific protein coatings with pancreatic cancer stages. This opens a new market for specialized diagnostic nanoparticles.
If you are a diagnostic laboratory dealing with high mortality rates in pancreatic cancer due to late diagnosis — this project developed a reactant-free laser test that could reduce mortality by as much as 80% through early detection. This provides a high-value, non-invasive service for aging populations.
Based on available project data, specific pricing is not mentioned, but the technique is described as cost-effective and reactant-free, which suggests lower operational costs than chemical-based tests.
Yes, the project objective specifically mentions providing the foundation for an in vitro test designed for large scale screening of the population.
Based on available project data, there is no specific mention of patents or licensing terms, though the project is led by an SME (FLIM LABS SRL) focused on developing a prototype.
The project period is set from 2024-01-01 to 2027-12-31, indicating a four-year development window.
The test is designed as an in vitro diagnostic (IVD) blood test, meaning it can be integrated into standard blood sampling and laboratory analysis workflows.
The consortium is well-balanced for a high-risk project, consisting of 7 partners across 4 countries. With an industry ratio of 43% and 3 SMEs involved, including the coordinator FLIM LABS SRL, there is a strong drive toward commercialization. The mix of 2 universities and 1 research institute ensures the scientific rigor needed for the complex biophotonic analysis.
Contact FLIM LABS SRL in Italy for partnership opportunities regarding FL analysis prototypes.
Contact us to explore licensing opportunities for the LaserBlood diagnostic prototype.
